Literature DB >> 20696135

Novel protein interactors of urokinase-type plasminogen activator receptor.

Ahmed H Mekkawy1, Charles E De Bock, Zhen Lin, David L Morris, Yao Wang, Mohammad H Pourgholami.   

Abstract

The urokinase-type plasminogen activator receptor (uPAR) has been implicated in tumor growth and metastasis. The crystal structure of uPAR revealed that the external surface is largely free to interact with a number of proteins. Additionally, due to absence of an intracellular cytoplasmic protein domain, many of the biological functions of uPAR necessitate interactions with other proteins. Here, we used yeast two-hybrid screening of breast cancer cDNA library to identify hSpry1 and HAX1 proteins as putative candidate proteins that interact with uPAR bait constructs. Interaction between these two candidates and uPAR was confirmed by GST-pull down, co-immunoprecipitation assays and confocal microscopy. These novel interactions that have been identified may also provide further evidence that uPAR can interact with a number of other proteins which may influence a range of biological functions. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696135     DOI: 10.1016/j.bbrc.2010.08.010

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  SPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferation.

Authors:  Xiufeng Liu; Yan Lan; Di Zhang; Kai Wang; Yao Wang; Zi-Chun Hua
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

2.  Urokinase-type plasminogen activator receptor (uPAR)-mediated regulation of WNT/β-catenin signaling is enhanced in irradiated medulloblastoma cells.

Authors:  Swapna Asuthkar; Christopher S Gondi; Arun Kumar Nalla; Kiran Kumar Velpula; Bharathi Gorantla; Jasti S Rao
Journal:  J Biol Chem       Date:  2012-04-16       Impact factor: 5.157

3.  Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers.

Authors:  Ji-Hyun Lee; Xing-Ming Zhao; Ina Yoon; Jin Young Lee; Nam Hoon Kwon; Yin-Ying Wang; Kyung-Min Lee; Min-Joo Lee; Jisun Kim; Hyeong-Gon Moon; Yongho In; Jin-Kao Hao; Kyung-Mii Park; Dong-Young Noh; Wonshik Han; Sunghoon Kim
Journal:  Cell Discov       Date:  2016-08-30       Impact factor: 10.849

4.  Human Sprouty1 suppresses growth, migration, and invasion in human breast cancer cells.

Authors:  Ahmed H Mekkawy; Mohammad H Pourgholami; David L Morris
Journal:  Tumour Biol       Date:  2014-02-08

5.  Differential roles of uPAR in peritoneal ovarian carcinomatosis.

Authors:  Nada N Al-Hassan; Ali Behzadian; Ruth Caldwell; Vessela S Ivanova; Viqar Syed; Kouros Motamed; Neveen A Said
Journal:  Neoplasia       Date:  2012-04       Impact factor: 5.715

6.  HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor.

Authors:  Ahmed H Mekkawy; David L Morris; Mohammad H Pourgholami
Journal:  J Oncol       Date:  2012-01-17       Impact factor: 4.375

7.  Human sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion.

Authors:  Ahmed H Mekkawy; David L Morris
Journal:  ISRN Biochem       Date:  2013-09-12

8.  Comment on "HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor".

Authors:  Alicja Trebinska; Ryszard Konopinski; Ewa A Grzybowska
Journal:  J Oncol       Date:  2013-05-22       Impact factor: 4.375

9.  The expression of the Sprouty 1 protein inversely correlates with growth, proliferation, migration and invasion of ovarian cancer cells.

Authors:  Samar Masoumi-Moghaddam; Afshin Amini; Anahid Ehteda; Ai-Qun Wei; David Lawson Morris
Journal:  J Ovarian Res       Date:  2014-06-08       Impact factor: 4.234

Review 10.  The developing story of Sprouty and cancer.

Authors:  Samar Masoumi-Moghaddam; Afshin Amini; David Lawson Morris
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.